AHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
American Healthcare REIT Inc (AHR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows positive long-term growth potential, supported by strong fundamentals in the healthcare REIT sector, favorable analyst ratings, and robust demand for senior housing and integrated health campuses. Despite insider selling and a slight decline in net income, the company's raised guidance and strong NOI growth make it a compelling long-term investment.
The technical indicators are bullish. The MACD histogram is positive and contracting, suggesting upward momentum. The RSI is neutral at 70.961, and the stock is trading above its key moving averages (SMA_5 > SMA_20 > SMA_200), indicating a strong uptrend. Support is at 47.35, and resistance levels are at 52.715 and 54.372.
Neo Ivy Capital Management acquired a significant stake, indicating institutional confidence.
The company reported a 16.4% same-store NOI growth in Q3, driven by senior housing and integrated health campuses.
Management raised full-year NFFO guidance to $1.69-$1.72 per share.
Analysts have given positive ratings, with price targets ranging from $52 to $55, reflecting optimism about the company's future performance.
Insiders are selling, with a 148.13% increase in selling activity over the last month.
Net income and EPS have significantly dropped YoY, raising concerns about profitability.
Hedge funds are neutral, indicating no strong institutional buying trends.
In Q3 2025, the company reported a revenue increase of 9.38% YoY to $572.94 million. However, net income dropped significantly to $55.93 million (-1455.48% YoY), and EPS fell to 0.33 (-1200.00% YoY). Despite these declines, gross margin improved slightly to 19.13%. Management's raised guidance and strong NOI growth highlight potential for recovery and long-term growth.
Analysts are generally positive on AHR. BMO Capital initiated coverage with an Outperform rating and a $55 price target, citing robust demand/supply fundamentals. Truist adjusted its price target to $52, maintaining a Buy rating, and remains bullish on healthcare REITs. Citi raised its price target to $52 but kept a Neutral rating, reflecting a more cautious stance. Overall, analysts see strong potential in the healthcare REIT sector, particularly for AHR.
